A clinical trial to investigate MRI and C-reactive protein levels at baseline as predictors of response to etanercept in patients with non-radiographic axial spondyloarthritis

Trial Profile

A clinical trial to investigate MRI and C-reactive protein levels at baseline as predictors of response to etanercept in patients with non-radiographic axial spondyloarthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2016 New trial record
    • 11 Nov 2015 Primary endpoint 'ASAS40' has been met, according to results presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top